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CHAPTER ONE
INTRODUCTION
Significance
Bipolar disorder (BD) is a chronic psychiatric illness affecting at least 1%
of the world population. It is characterized by fluctuations between manic and
depressed mood states. With an attempted suicide rate of 25-50% (Jamison,
2000), it is the psychiatric condition most commonly associated with suicide. The
Global Burden of Disease report documented BD as the sixth greatest cause of
death or disability globally (Narrow et al., 2002). Approximately 10.3% of all costs
of global biomedical illnesses are attributed to BD (Andreasen, 2001). Patients
with BD generally experience high rates of relapse, chronicity, residual
symptoms, cognitive and functional impairment, as well as psychosocial disability
leading to damaged relationships and poor job or school performance. A number
of medications are used to treat BD. However, none of the drugs prescribed to
treat BD are completely effective, and the development of more effective drugs
with fewer side-effects is hampered by the lack of knowledge of the therapeutic
mechanism of action of these drugs and the molecular mechanism underlying
BD. Therefore, to improve the treatment of BD, it is important to understand the
therapeutic mechanisms of action of current drugs.
Treatments for BD
Medications known as “mood stabilizers” such as lithium, valproate (VPA)
and lamotrigine are used to treat BD. Atypical antipsychotics have also been
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used, but most research has focused on lithium and VPA. VPA, the subject of
this research, is a widely prescribed and established anticonvulsant that was
approved by the FDA in 1995 as a mood stabilizer to treat BD. It is a simple
branched-chain fatty acid (2-propylpentanoic acid; 2-propylvaleric acid; di-npropylacetic acid) that was found to be an anticonvulsant in 1962 during a screen
for compounds having anti-seizure activity (as reviewed by Henry, 2003). In spite
of the wide usage of VPA, many side effects have been identified. The clinical
side effects of VPA include sedation, gastrointestinal symptoms, tremor and a
benign increase in hepatic transaminase levels, dyspepsia, weight gain,
dysphoria, fatigue, dizziness, drowsiness, hair loss, headache and nausea
(reviewed by Kostrouchova et al., 2007). When used in early pregnancy, VPA
causes a 3-fold increased risk of congenital anomalies such as neural tube
defects resulting in spina bifida (Lammer et al., 1987; Koren and Kennedy, 1999;
Koren et al., 2006). Another major drawback of VPA is that 20%–40% of patients
fail to respond satisfactorily. All of these negative effects highlight a great need to
develop more effective drugs to treat BD. However, the molecular mechanism of
the therapeutic action of VPA in BD is still unknown. A known target of VPA is
inositol metabolism (O’Donnell et al., 2000; Vaden et al., 2001; Shaltiel et al.,
2004; Williams et al., 2002). Decreased inositol also results from treatment with
lithium. The work in this dissertation focuses on the effects of VPA on inositol
metabolism.
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Biosynthesis and importance of inositol
Inositol is an essential molecule ubiquitously found in all biological
systems. It is a six carbon cyclitol that exists in nine possible isomeric forms
(myo, L- chiro, D-chiro, scyllo, neo, cis, epi, allo, and muco). Of these, myoinositol is physiologically the most common and important isomer (Shi et al.,
2005). Inositol biosynthesis occurs in two steps. In the first step, glucose-6phosphate is converted to L-myo-inositol-3-phosphate (MIP) by 1D-myo-inositol3 phosphate synthase (MIPS) (Donahue and Henry, 1981). Myo-inositol
monophosphatase (IMPase) is the second enzyme in the pathway, which
converts MIP into free myo-inositol (Majumder et al., 1997). In yeast, MIPS is
encoded by INO1 while INM1 encodes IMPase. Phosphorylation of the inositol
ring at one or more positions generates numerous phosphoinositides (PIs) and
inositol phosphates (IPs) (Fig 1).
Inositol plays an important role in several cellular processes, including
protein secretion, growth regulation, signal transduction, transcription regulation,
and membrane biogenesis (Carman and Henry, 1999; Lohia et al., 1999; Fisher
et al., 2002). A number of genes show altered expression in response to inositol
(Nikoloff and Henry, 1991; Paultauf et al., 1992; Lopes et al., 1991; Bailis et al.,
1992). These include genes that affect the processes of lipid biosynthesis,
protein folding and secretion, vacuole fusion, and others (Jesch et al., 2005).
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Figure 1: Inositol metabolism: Yeast obtain inositol in three ways: uptake of inositol
from extracellular fluid by inositol transporters (Itr1p and Itr2p), turnover of inositol
containing phospholipids, and de novo synthesis. Inositol biosynthesis is a two-step
pathway: 1D-myo-inositol-3 phosphate synthase (MIPS) converts glucose-6-phosphate
to inositol-3-phosphate (MIP), which is converted to free myo-inositol by myo-inositol
monophosphatase (IMPase). Inositol is converted to phosphatidylinositol, then to other
phosphoinositides (PIs) and inositol phosphates (IPs) in the PI cycle. VPA causes
inositol depletion by indirect inhibition of MIPS. IP6 inhibits INO1 expression. Current
Hypothesis: Loss of KCS1 and VIP1 lead to inositol depletion, causing sensitivity to
VPA.
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neuropsychiatric disorders such as BD, Parkinson’s disorder, and Alzheimer’s
disease (Silverstone et al., 2002; LaFerla, 2002). All of these factors emphasize
the importance of understanding the effect of VPA on inositol metabolism to
elucidate its therapeutic mechanism of action.
Inositol metabolism and VPA
Evidence shows that VPA interferes with inositol metabolism in yeast
(O’Donnell et al., 2000; Shaltiel et al., 2004; Williams et al., 2002). VPA
decreases de novo synthesis of inositol by indirectly inhibiting MIPS activity in
vivo in yeast (Vaden et al., 2001; Ju et al., 2004). Yeast cells grown in the
presence of VPA exhibited decreased intracellular inositol and an increase in the
expression of the structural gene INO1 and the regulatory gene INO2, consistent
with inositol depletion (Vaden et al., 2001). Some evidence suggests that VPA
also interferes with inositol metabolism in mammals. VPA was found to decrease
activity of human MIPS expressed in yeast cells (Ju et al., 2004) and activity of
MIPS in crude homogenates of human postmortem prefrontal cortex (Shaltiel et
al., 2004). Further, VPA reduced brain inositol levels in a magnetic resonance
spectroscopy study in rats (O'Donnel et al., 2000). Another study showed that
VPA decreased growth cone collapse and increased growth cone area of rat
sensory neurons in culture. These effects were eliminated by supplementation
with inositol (Williams et al., 2002). All of these studies support that VPA depletes
inositol levels and affects inositol metabolism.
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IPs are important molecules in inositol metabolism
IP3, produced by the cleavage of phosphatidylinositol bisphosphate (PIP2)
by PI-specific phospholipase C (PLC), is further phosphorylated to synthesize
other IPs (Berridge and Irvine, 1989; Majerus, 1992). These IPs include inositol
tetrakisphosphate

(IP4),

inositol

pentakisphosphate

(IP5),

and

inositol

hexakisphosphate (IP6) that are generated through the subsequent action of
several classes of evolutionarily conserved inositol phosphate kinases (IPKs)
(Irvine and Schell, 2001; York, 2006; Communi et al., 1994; Shears, 2004). IPs
have been shown to convey signals for a variety of hormones, growth factors,
and neurotransmitters (Berridge, 1993; Berridge and Irvine, 1989). Among all
IPs, IP3 and IP6 are the most highly studied in relation to human disease.
IP3 is synthesized by the PLC catalyzed hydrolysis of PIP2 (Strahl and
Thorner, 2007). IP3 is phosphorylated to IP4 and, IP4 is further phosphorylated
to IP5 by inositol polyphosphate multikinase (IPK2). IP5-kinase (IPK1)
phosphorylates IP5 to generate IP6 (York et al., 1999), and IP6 is further
phosphorylated to IP7 and IP8 by Kcs1p and Vip1p, hexakisphosphate kinases
(IP6Ks) (Luo et al., 2003; Huh et al., 2003). IP3 plays an essential role as a
second messenger in the IP3/Ca2+ signal transduction pathway that is
responsible for modulating the activity of numerous cellular processes. IP6 is the
most abundant inositol phosphate and is found in all mammalian cells. It exhibits
strong antioxidant properties (Hawkins et al., 1993) and causes inhibition of Fe3+catalyzed hydroxyl-radical formation. Other functions of IP6 include inhibition of
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protein phosphatases (Larsson et al., 1997) and activation of PKC (Efanov et al.,
1997). Anticancer properties have been reported (Fox and Eberl, 2002; Vucenik
and Shamsuddin, 2003). IP6 is also found in the yeast nucleus and modulates
mRNA transport out of the nucleus (York et al., 1999).
An important effect of IP6 on inositol metabolism is the inhibition of
nucleosome mobilization of the INO80 complex that positively regulates INO1
expression (Ford et al., 2007; Shen et al., 2003). However, the effect of IP6 on
INO1 expression has not been studied. The de novo synthesis of inositol and IPs
are characterized in the greatest detail in the yeast Saccharomyces cerevisiae,
and very little is known about inositol metabolism in human cells (reviewed in
Azab et al., 2008). Therefore, yeast is an ideal model system to carry out
research to understand the effect of VPA on inositol metabolism and IPs.
Yeast as a model system
The baker’s yeast S. cerevisiae has been used as a eukaryotic model
organism to study the effect of VPA on inositol metabolism (Ju and Greenberg,
2003; Ju et al., 2004; Vaden et al., 2001). Yeast can be easily used for genetic,
molecular, and biochemical approaches. The complete sequence of the yeast
genome and the disruption mutants of all nonessential genes are available. Many
of the genes that encode components of the PI pathway have been cloned in
yeast, and regulation of inositol metabolism in yeast is well characterized at a
molecular level (Greenberg and Lopes, 1996).
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A high degree of conservation of function between yeast and higher
eukaryotes indicates that the yeast system can be utilized to understand complex
eukaryotic cellular processes. Conservation of function with respect to inositol
metabolism has been demonstrated from yeast to humans, and homologs of the
yeast genes INO1 and INM1 are present in the human genome. Human MIPS
and yeast INO1 exhibited 56% amino acid similarity, and human IMPA1 and
yeast INM1 shared 43% similarity (www.ncbi.nlm.nih.gov). In addition, the
expression of human MIPS complements the inositol auxotrophy of yeast ino1
null mutants (Ju et al., 2004). It has also been shown that human MIPS is
inhibited by VPA (Ju et al., 2004; Shaltiel et al., 2004).

O’ Brien et al., (1990)

showed that at least 40% of the genes responsible for heritable diseases in
humans have counterparts in yeast. S. cerevisiae has been successfully used as
a model for understanding pathogenic mechanisms in Huntington’s disease (HD)
and Parkinson’s disease (PD) (Willingham et al., 2003). These studies
demonstrate that yeast is a powerful system that can be utilized to study the
effect of VPA on IPs and inositol depletion.
Project outline
In yeast, VPA causes inositol depletion by indirectly inhibiting MIPS
encoded by INO1 (Vaden et al., 2001; Ju et al., 2004). Factors that regulate
INO1 expression in yeast include the transcriptional activators Ino2p/ Ino4p
(Koipally et al., 1996; Schwank et al., 1995), intracellular inositol levels (Heyken
et al., 2005) and chromatin remodeling complexes (Shen et al., 2000). The
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INO80 chromatin remodeling complex positively regulates chromatin remodeling
at the yeast INO1 promoter (Ford et al., 2007). In yeast, IP6 inhibits the activity of
the INO80 complex (Shen et al., 2003), suggesting that increased IP6 may lead
to decreased INO1 expression. KCS1 and VIP1 convert IP6 to IP7 (Luo et al.,
2003; Lin et al., 2009), and loss of KCS1 and VIP1 leads to increased
intracellular IP6 levels (Dubois et al., 2002; Mulugu et al., 2007). Therefore, I
hypothesized that perturbation of these pathways may inhibit inositol synthesis
and increased VPA sensitivity.
To test the hypothesis, I screened deletion mutants of all genes reported
to affect inositol metabolism for inositol auxotrophy. kcs1∆ was identified as an
inositol auxotroph in this screen. I further characterized kcs1∆ with respect to
inositol metabolism and VPA sensitivity. My results showed that loss of KCS1
caused VPA sensitivity due to inositol depletion. Because kcs1∆ causes
increased IP6 levels, I tested other mutants in the IP pathway to determine if
other mutants that perturb IP6 cause inositol auxotrophy. Of the mutants tested,
(ipk1∆, ipk2∆, plc1∆ and vip1∆), vip1∆, which increases IP6 exhibited partial
inositol auxotrophy and VPA sensitivity in contrast to the other mutants, which
most likely do not affect IP6 levels. In summary, the loss of KCS1 or VIP1
exacerbates VPA induced inositol depletion. As discussed above, about 50% of
patients with BD do not respond to VPA (Dilsaver at al., 1993). The current study
may be relevant to understanding the genetic factors that contribute to
responsiveness to this drug.
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CHAPTER TWO
MATERIALS AND METHODS
Materials
All chemicals and reagents used were reagent grade or better. Amino
acids, myo-inositol and VPA were purchased from Sigma. Vitamin supplements
were purchased from Difco. Glucose was purchased from Fisher Scientific. Agar
was bought from US Biological (Swampscott, MA). Chloroform, methanol,
ethanol, acid phenol (pH 4.3) and Tris-HCl were bought from Fisher. RNeasy
Mini Kit was purchased from Qiagen. Transcriptor first strand synthesis kit and
Dna free kit were purchased from Roche and Ambion. Brilliant SYBR green
QPCR and 8X optical strip tubes were purchased from Stratagene.
Growth media
Synthetic complete (SC) medium with inositol (I+SC) contained glucose
(2% w/v), necessary amino acids: adenine, arginine, histidine, methionine,
tryptophan (20 mg/L), lysine (200 mg/L), uracil (40 mg/L), and leucine (60 mg/L),
inositol (75µM), ammonium sulphate (0.2% w/v), vitamins (Culbertson and Henry,
1975) and the components of vitamin-free yeast base: boric acid (200 µg/l),
calcium chloride (80 µg/l), magnesium sulfate (0.2 g/l), potassium iodide (40
µg/l), potassium phosphate monobasic (0.4 g/l), sodium molybdate (80 µg/l), and
zinc sulfate (160 µg/l), plus agar (2% w/v) for solid medium. Synthetic complete
medium without inositol (I-SC) contained all of the above mentioned ingredients
except inositol. Synthetic minimal (SM) medium with inositol (I+SM) contained all

11

the necessary ingredients as mentioned for I+SC except adenine, arginine and
lysine. Synthetic minimal medium without inositol (I-SM) contained all of the
components in I+SM except inositol. Complex medium (YPD) contained glucose
(2% w/v), bacto-peptone (2% w/v), agarose (2%w/v), and yeast extract (1% w/v
Agar (2% w/v) was added to the above mentioned medium for solid medium.
Cells were grown at 30C unless otherwise indicated.
Yeast strains
All the deletion mutants were derived from the deletion collection and were
isogenic with BY4741 (his3∆1, leu2∆0, met15∆0, ura3∆0) but carried the deletion
of the specific gene. The list of mutants is given in Table1.
Growth conditions
To compare growth patterns, cells were initially grown in liquid YPD
medium and inoculated to an A550 of 0.01 in SM and SC liquid media with or
without inositol. To assay inositol-less death, liquid cultures were inoculated from
cultures grown in the presence of 75 µM inositol for 24 h.
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Table 1: Deletion mutants screened for inositol auxotrophy (as described in
the S. cerevisiae Genomic Data base)
Group

Kinases

Deletion Protein encoded

Function of the protein

mutant

by the gene

(Cited directly from SGD)

kcs1∆

IP5/IP6/IP7 kinase

Generates high energy inositol
pyrophosphates required for
cellular processes such as
vacuolar biogenesis, stress
response and telomere
maintenance

ipk1∆

IP5 kinase

Required for synthesis of IP6

ipk2∆

Inositol polyphosphate

Sequentially phosphorylates

multikinase

IP3 to form IP5; also has
diphosphoinositol
polyphosphate synthase
activity

vip1∆

IP6/IP7 kinase

Generates IP7 required for
phosphate signaling; likely
involved in cortical actin
cytoskeleton function
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ire1∆

Serine-threonine

Mediates the unfolded protein

kinase

response (UPR) by regulating
Hac1p synthesis

tos3∆

Protein kinase

Involved in phosphorylation
and activation of Snf1p;
functionally orthologous to
LKB1, a mammalian kinase
associated with Peutz-Jeghers
cancer-susceptibility syndrome

ypk1∆

Protein

Involved in control of

serine/threonine/tyrosi

chromosome segregation and

ne kinase

in regulating entry into meiosis;
related to mammalian
glycogen synthase kinases of
the GSK-3 family

rck1∆

Protein kinase

Involved in the response to
oxidative stress; identified as
suppressor of S. pombe cell
cycle checkpoint mutations
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lsb6∆

Type II

Binds Las17p, which is a

phosphatidylinositol 4-

homolog of human

kinase

Wiskott-Aldrich Syndrome
protein involved in actin patch
assembly and actin
polymerization

Phosphatases

ddp1∆

Polyphosphate

Hydrolyzes diphosphorylated

phosphatase

IPs and diadenosine
polyphosphates; has high
specificity for diadenosine
hexa- and pentaphosphates

ymr1∆

Phosphatidylinositol 3-

Involved in various protein

phosphate (PI3P)

sorting pathways, including

phosphatase

CVT targeting and endosome
to vacuole transport
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dpp1∆

Diacylglycerol

Zinc-regulated vacuolar

pyrophosphate

membrane-associated lipid

(DGPP) phosphatase

phosphatase,
dephosphorylates DGPP to
phosphatidate (PA) and PI,
then PA to diacylglycerol;
involved in lipid signaling and
cell metabolism

Vacuolar

vac1∆

proteins

Multivalent adaptor

Facilitates vesicle-mediated

protein

vacuolar protein sorting by
ensuring high-fidelity vesicle
docking and fusion

vac7∆

Integral vacuolar

Involved in vacuole inheritance

membrane protein

and morphology; activates
Fab1p kinase activity under
basal conditions and also after
hyperosmotic shock

avt4∆

Vacuolar transporter

Exports large neutral amino
acids from the vacuole
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vac14∆

Protein involved in regulated Involved in control of
synthesis of PtdIns(3,5)P(2) trafficking of some
proteins to the vacuole
lumen via the MVB, and in
maintenance of vacuole
size and acidity; interacts
with Fig4p; activator of
Fab1p

Membrane

csg2∆

proteins

Endoplasmic reticulum

Required for

(ER)membrane protein

mannosylation of
inositolphosphorylceramid
e and for growth at high
calcium concentrations

git1∆

Plasma membrane

Mediates uptake of

permease

glycerophosphoinositol
and
glycerophosphocholine as
sources of the nutrients
inositol and phosphate;
expression and transport
rate are regulated by
phosphate and inositol
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scs2∆

Integral ER membrane

Regulates phospholipid

protein

metabolism via an
interaction with the FFAT
motif of Opi1p, also
involved in telomeric
silencing

Transferases

cpt1∆

Cholinephosphotransferase

Required for
phosphatidylcholine
biosynthesis and for
inositol-dependent
regulation of EPT1
transcription

ipt1∆

Inositolphosphotransferase

Involved in synthesis of
mannose-(inositol-P)2ceramide (M(IP)2C), the
most abundant
sphingolipid , can mutate
to resistance to the
antifungals syringomycin
E and DmAMP1 and to K.
lactis zymocin
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Other

ubx6∆

mutants

UBX (ubiquitin regulatory X)

Interacts with Cdc48p.

domain-containing protein

Transcription of UBX6 is
repressed when cells are
grown in media containing
inositol and choline

mtd1∆

NAD-dependent 5,10-

plays a catalytic role in

methylenetetrahydrafolate

oxidation of cytoplasmic

dehydrogenase

one-carbon units;
expression is regulated by
Bas1p and Bas2p,
repressed by adenine, and
may be induced by inositol
and choline

opi10∆

Over producer of inositol

Involved in phospholipid
biosynthesis

ctr1∆

Choline/ethanolamine

Involved in uptake of

transporter

nitrogen mustard and the
uptake of glycine betaine
during hypersaline stress
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hor7∆

Protein of unknown function

Overexpression
suppresses Ca2+
sensitivity of mutants
lacking inositol
phosphorylceramide
mannosyltransferases
Csg1p and Csh1p;
transcription is induced
under hyperosmotic stress

tep1∆

Homolog of human tumor

Has lipid phosphatase

suppressor gene

activity and is linked to the

PTEN/MMAC1/TEP1

phosphatidylinositol
signaling pathway; plays a
role in normal sporulation
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The cells were harvested by low speed centrifugation at room temperature,
washed twice with inositol-free (I-) medium, and reinoculated in I+ or I-media to
an A550 of approximately 0.1 at time zero. Cells were grown at 300C in a rotary
shaker at 200 rpm. Cell number was calculated by microscopic counting using a
hemocytometer every two hours. To determine viable cells, serial dilutions were
plated on YPD and colonies were counted.
Determining hypersensitivity to VPA
Cells were grown in liquid SM and SC media with or without inositol to the
logarithmic phase of growth, at which time different concentrations of VPA were
added as indicated. A550 was measured every six hours. Cells were also plated
on liquid SM and SC media with the same concentrations of inositol and VPA as
used in the liquid cultures. The concentrations of VPA are given in mM.
Real-time PCR
Cells were grown to the early stationary phase in the presence or absence
of VPA (0.6 mM) and were harvested by centrifugation at 3500 rpm for 10 min.
Total RNA was isolated using the hot phenol extraction method (Elion and
Warner, 1984). 50 µl of total RNA was passed through a Qiagen gDNA column
to remove genomic DNA. The sample was then applied to a Qiagen RNeasy spin
column to enrich for mRNA. cDNAs were synthesized with a Transcriptor First
Strand cDNA Synthesis Kit (Roche Biochem) according to the manufacturer’s
protocol. Real-time PCR reactions were performed in a 25 µl volume using
Brilliant SYBR Green QPCR Master Mix (Stratagene) in 8X optical strip tubes
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from Stratagene. cDNA for each sample was synthesized in duplicate and each
cDNA was amplified in triplicate during the RT-PCR reaction. The primers used
in real-time PCR are listed in Table 2. ACT1 was used as the internal control and
the RNA level of INO1 was normalized to ACT1 levels in all samples. The
protocol for the RT-PCR reaction is as follows: denature at 95C for 10 min
followed by 40 cycles consisting of 60 s at 95C and 60 s at 57C.
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Table 2: The real-time PCR primers used in this study
Gene (bp)

INO1

ACT1

Primers

Sequence

Forward

5’-AGTCTGTTCTGGCCCAGTTCTTAG-3’

Reverse

5’-CGGTTATGGCCACCTAACATCAAC-3’

Forward

5’-TCGTGCTGTCTTCCCATCTATCG-3’

Reverse

5’CGAATTGAGAGTTGCCCCAGAAG-3’

Product length

210

218
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CHAPTER THREE
RESULTS
Screen of deletion mutants to identify inositol auxotrophs
Deletion mutants of genes that affect inositol metabolism (Table 1) were
screened for inositol auxotrophy. Cells were plated on both YPD and SM plates
in the presence and absence of inositol and incubated at 30oC. Three potential
inositol auxotrophs were identified, kcs1∆ (Fig 2-B), vac7∆ (Fig 2-A) and vac14∆
(Fig 2-C). Growth of kcs1∆ but not the others was restored by inositol. Therefore,
kcs1∆ was subjected to further analysis.
Inositol auxotrophy of kcs1∆
The growth of kcs1∆ was compared to that of the MIPS mutant ino1∆.
Isogenic WT, kcs1∆ and ino1∆ cells were grown in liquid SM at 30oC in the
presence and absence of inositol. Both kcs1∆ and ino1∆ exhibited a marked
decrease in growth compared to the WT in liquid or solid I-SM medium (Fig 3 and
4). Growth was restored by supplementation of inositol. A more stringent test of
inositol auxotrophy, inositol-less death, was compared in both ino1∆ and kcs1∆.
Cells of ino1∆ and kcs1∆ were grown in I+ SM medium and immediately shifted
to I-SM and I+SM media.

24

A

C

YPD I-SM I+SM

ire1∆

YPD I-SM I+SM

B

csg2∆

ddp1∆
tos3∆

vac7∆

cpt1∆

ymr1∆

kcs1∆

ubx6∆

mtd1∆

ypk1∆
avt4∆
rck1∆
hor7∆
vac14∆

D

git1∆
dpp1∆
opi10∆
, ctr1∆
lsb6∆
∆

E
ipt1∆
scs2∆
vac1∆
tep1∆

Figure 2: kcs1Δ is an inositol auxotroph
Wild type (WT) and deletion mutant cells were grown to the logarithmic phase
in liquid YPD. Cell number was determined using a haemocytometer slide, and 10 4
cells/ml were spotted on YPD and SM plates in the presence or absence of inositol.
The plates were incubated at 30oC for 4 days. Arrow (
growth of inositol auxotrophs.

) indicates the pattern of
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Figure 3: Decreased growth of kcs1∆ in the absence of inositol
WT, kcs1∆ and ino1∆ cells were grown in liquid SM at 30°C, in the
presence and absence of inositol. Growth was followed by measuring A550. The
data are representative of two independent experiments in which duplicate
samples were measured.
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Figure 4: Decreased growth of kcs1∆ in the absence of inositol
WT and kcs1Δ cells were grown in liquid YPD for 24 hrs at 30oC. Cells
were washed twice and cell number was determined using a haemocytometer
slide and serially diluted cells were spotted (103 cells/ml, 102cells/ml, 101 cells/ml)
on SC plates in the presence or absence of inositol (75 µM). The plates were
incubated at 30oC for 4 days.
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Viable cells were measured at the times indicated. As seen in Fig. 5, both
mutants exhibited inositol-less death, although kcs1∆ was slightly less sensitive
to inositol starvation compared to ino1∆. Taken together, these experiments
indicate that kcs1∆ is an inositol auxotroph.
Determination of VPA hypersensitivity of kcs1∆
Because kcs1∆ is an inositol auxotroph, I hypothesized that the mutant is
hypersensitive to VPA. To test the VPA sensitivity of kcs1∆, growth of kcs1∆ was
compared to that of WT in the presence of VPA. First, cells were plated on I+SM
in the presence of 0-0.6 mM VPA. Growth was monitored for 3-4 days. As shown
in Fig 6, the growth of kcs1∆ was more sensitive to VPA than that of WT. To
further analyze the growth of kcs1∆ in the presence of VPA, cells were grown in
liquid media to the logarithmic phase of growth, at which time VPA (range 0 - 0.6
mM) was added. The results obtained in the growth curves showed a gradual
decrease in growth with increased concentrations of VPA in liquid cultures (Fig
7). It is clearly seen that the growth of kcs1∆ is more sensitive to VPA than that of
WT at each concentration of VPA tested.
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Figure 5: kcs1∆ undergoes inositol-less death
Cells of ino1∆ and kcs1∆ were grown overnight in I+ SM media at 30oC.
Cells were harvested, washed twice with I-SM medium, and immediately shifted
to I+ or I-media at an A550 of approximately 0.1 at time zero. Cells were harvested
at the indicated times, serially diluted, plated on YPD plates, and incubated at
30°C for 9 h. The number of viable cells was determined as described in
Materials and Methods.
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Figure 6: kcs1Δ is hypersensitive to VPA
WT and kcs1Δ cells were grown in liquid YPD for 24 hrs at 30oC. Cells
were washed twice, cell number was determined using a haemocytometer slide,
and serially diluted cells were spotted (105 cells/ml 104 cells/ml 103 cells/ml, 102
cells/ml and 101 cells/ml) on SM plates in the presence or absence of inositol
(75µM) and with different concentrations of VPA (mM) added as indicated. The
plates were incubated at 30oC for 4 days.
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Figure 7: kcs1Δ is hypersensitive to VPA
WT and kcs1∆ cells were grown in liquid I+SM at 30°C, in the presence of
the indicated concentrations of VPA. A550 of the cultures in the stationary phase
was determined. The data are representative of two independent experiments in
which duplicate samples were measured.
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Quantification of INO1 expression in kcs1∆
As discussed above, INO1 expression is positively regulated by the INO80
complex, which rearranges the nucleosomes at the INO1 promoter (Ford et al.,
2007). Shen et al (2003) showed that IP6 inhibits INO80-induced nucleosome
mobilization by inhibiting its ATPase activity. As Kcs1p converts IP6 to IP7 (Luo
et al., 2003), I hypothesized that loss of KCS1 is expected to lead to increased
IP6 levels and the subsequent down-regulation of INO1 expression, which could
explain the inositol auxotrophy of the kcs1∆ deletion mutant. To test this
possibility, INO1 expression levels were measured by real time-PCR in I+ (75µM)
medium, as kcs1∆ does not grow in the absence of inositol. As shown in Fig 8,
INO1 expression in kcs1∆ showed a 5-fold decrease compared to that of WT in
the stationary phase.
Interestingly, although VPA caused increased INO1 expression in
response to inositol depletion in WT (Fig 9-A), consistent with previous studies
(Vaden et al., 2001), kcs1∆ did not show a significant increase in INO1
expression in the presence of VPA (Fig 9-B). Therefore, the inability of kcs1∆ to
increase INO1 expression in response to inositol depletion might explain the
sensitivity of the mutant to VPA.
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Figure 8: Loss of KCS1 causes decreased INO1 expression
WT and kcs1Δ cells were grown in I+SM medium at 30oC to the stationary
phase. Total RNA was extracted and INO1 mRNA levels were measured by realtime PCR. INO1 expression levels were normalized to the levels of the internal
control gene ACT1. The fold change of INO1 expression was calculated with
respect to WT. Data are representative of two independent experiments in
duplicate samples.

33

WT

A

5
3
2
1
0

with

INO1/ACT1

4

WT _
/VPA-

WT /VPA+
+

kcs1∆

B

0.1
0.05
0

with

INO1/ACT1

0.15

_

kcs1 /VPA-

kcs1+/VPA+

Figure 9: VPA does not increase INO1 expression in kcs1∆
WT (A) and kcs1Δ (B) cells were grown in I+SM medium in the presence
(+) or absence (-) of 0.6 mM VPA at 30oC to the stationary phase. Total RNA was
extracted and INO1 mRNA levels were measured by real-time PCR. INO1
expression levels were normalized to the levels of the internal control gene
ACT1. Data are representative of two independent experiments in duplicate
samples.
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Inositol auxotrophy of vip1∆
The finding that kcs1∆ exhibited inositol auxotrophy suggested that
perturbation of other IP kinases and /or phosphatases might also lead to inositol
auxotrophy, particularly those affecting IP6 levels. Therefore, I analyzed ipk1∆,
ipk2∆, plc1∆ and vip1∆ for this phenotype.
Of these mutants, vip1∆ is expected to increase IP6 levels. As shown in
Fig 10-A, fewer colonies were observed in vip1∆ compared to WT on solid
medium in the absence of inositol. The growth of vip1∆ was analyzed further in
liquid cultures. As seen in Fig 12, growth was decreased in I-, and restored upon
supplementation with inositol. Although the loss of IPK2 did not show a
significant effect on growth compared to WT in the absence of inositol on solid
medium (Fig 10-B), ipk2∆ showed slightly less growth than that of WT in I- liquid
medium (11-C). Here, the growth was restored upon supplementation with
inositol. However, ipk1∆ and plc1∆ grew similar to WT in both liquid and solid
medium (Fig 10-A, 11-A & B).
VPA sensitivity of vip1Δ
As IP6K encoded by VIP1 converts IP6 into IP7 (York et al., 2005), the
loss of VIP1 might increase intracellular IP6 levels, causing inositol depletion and
VPA sensitivity. Growth of vip1Δ was compared to that of WT in both liquid and
solid media in the presence of VPA. Cells were plated on I- medium in the
presence of different concentrations of VPA. Growth was monitored for 3-4 days.
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Figure 10: vip1∆ shows partial inositol auxotrophy
Isogenic vip1Δ, ipk1Δ, plc1Δ, ipk2Δ and WT cells were grown in liquid
YPD for 24 hrs at 30oC. Cells were washed twice, cell number was determined
using a haemocytometer slide, and serially diluted cells (105 cells/ml, 104
cells/ml, 103 cells/ml, 102cells/ml, 101 cells/ml ) were spotted on SM plates in the
presence or absence of inositol (I) (A). The mutant ipk2Δ was spotted on SC
plates (B), because SM medium does not support the growth of this mutant. The
plates were incubated for 4 days.
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Figure 11: ipk1Δ, ipk2Δ and plc1Δ and are not inositol auxotrophs
Cells of ipk1Δ (A) and plc1Δ (B) were grown in liquid SM and ipk2Δ (C)
was grown in liquid SC in the presence and absence of inositol at 30 0C. Growth
was followed by measuring A550.
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Figure 12: vip1∆ exhibits decreased growth in Ivip1Δ was grown in liquid SM in the presence and absence of inositol at
300C, and growth was followed by measuring A550.
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As shown in Fig 13, vip1∆ was hypersensitive to VPA. Growth of mutants, ipk1∆,
ipk2∆ and plc1∆ was similar to WT. In order to further analyze the effects of VPA
on growth, cells were grown to the logarithmic phase, at which time VPA (0-0.6
mM) was added. A decrease in growth with increased concentrations of VPA was
seen throughout the growth cycle of vip1∆ (Fig 14), while ipk1∆, ipk2∆, and plc1∆
grew similar to WT (Figs 14 and 15).
The loss of VIP1 causes decreased INO1 expression
One possible explanation for inositol auxotrophy of vip1∆ is decreased
expression of INO1 in the mutant. Consistent with this, INO1 expression in vip1∆
was decreased 2-fold compared to that of WT in the stationary phase (Fig 16-A).
In contrast, plc1∆ and ipk2∆ did not show a significant change in INO1
expression (Fig 16-A and B). Interestingly, ipk1∆ exhibited a significant increase
in INO1 expression compared to WT (Fig16-A). As IPK1 converts IP5 to IP6, loss
of IPK1 may have caused decreased IP6 levels. As Vip1p also converts IP6 to
IP7 (Lin et al., 2009), it is likely that loss of VIP1 leads to elevated levels of IP6,
resulting in inhibition of the INO80 complex (Shen et al., 2003), similar to what
was observed for kcs1∆.
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Figure 13: vip1Δ is hypersensitive to VPA
WT, vip1Δ, ipk1Δ, ipk2∆ and plc1Δ cells were grown in liquid YPD for 24
hrs at 30oC. Cells were washed twice and cell number was determined using a
haemocytometer slide. Serially diluted cells (105 cells/ml 104 cells/ml 103 cells/ml,
102 cells/ml and 101 cells/ml) of WT, vip1Δ, ipk1Δ and plc1∆ were spotted on SM
plates (A) and ipk2Δ was spotted on SC plates (B) in the absence of inositol and
with different concentrations of VPA as indicated. The plates were incubated for
4 days.
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Figure 14: vip1Δ is sensitive to VPA
WT, vip1Δ, ipk1Δ and plc1Δ cells were grown to the stationary phase in
liquid I-SM at 30°C, in the presence of the indicated concentrations of VPA.
Growth was followed by measuring A550.
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Figure 15: ipk2Δ is not sensitive to VPA
WT and ipk2Δ cells were grown to the stationary phase in liquid I-SC at
30°C, in the presence of the indicated concentrations of VPA. Growth was
followed by measuring A550.
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Figure 16: Loss of VIP1 causes decreased INO1 expression
vip1Δ, ipk1Δ, plc1Δ, and WT (A) were grown in I-SM medium and ipk21Δ
(B) was grown in I-SC medium at 30oC to the stationary phase. Total RNA was
extracted and INO1 mRNA levels were measured by real-time PCR. INO1
expression levels were normalized to the levels of the internal control gene
ACT1. The fold change of INO1 expression was calculated with respect to WT.
Data are representative of two independent experiments in duplicate samples.
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CHAPTER FOUR
DISCUSSION
The major finding in this study is that deletion mutants of KCS1 and VIPI
genes that affect IP6 synthesis confer inositol auxotrophy and sensitivity to VPA.
KCS1 and VIPI are inositol kinases in the PI cycle. Kcs1p phosphorylates IP5 to
IP6, IP6 to IP7, and IP7 to IP8 (Luo et al., 2003; Saiardi et al., 2000). Vip1p is
also an IP6K, which phosphorylates the 4/6 positions of IP6 and IP7 while Kcs1p
phosphorylates the 5 position in IP4, IP6 and IP7. (Lin et al., 2009). Loss of
IP6Ks

results

in

pleiotropic

cellular

defects,

including

aberrant

DNA

recombination, abnormal vacuolar morphology, altered gene expression,
increased chemotaxis, osmotic stress, altered protein phosphorylation, and
decreased telomere length (York 2006, Bennett et al., 2006). The results shown
here indicate that KCS1 and VIPI are necessary for inositol biosynthesis, and this
may in part explain some of the cellular phenotypes observed in IP6K mutants.
The present study also demonstrates that both kcs1∆ and vip1∆ mutants
are hypersensitive to VPA. As discussed above, our lab has shown that VPA
causes inositol depletion, and that inositol supplementation rescues sensitivity to
VPA. Therefore, the most likely explanation for VPA sensitivity of these mutants
is that loss of KCS1 or VIP1 results in a decrease in inositol levels that
exacerbates the VPA induced inositol depletion. A key finding in this research is
that kcs1∆ and vip1∆ mutants exhibit decreased INO1 expression, suggesting
that the substrates and/or the products of KCS1 and VIP1 regulate INO1
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expression. As described earlier, increased IP6 due to the loss of KCS1 and
VIP1 might inhibit INO1 expression by affecting the chromatin remodeling
complex INO80.
In order to determine the relevance of this study to BD, it is important to
consider the current knowledge concerning the human homologs of KCS1, VIP1
and the INO80 complex, and how these factors affect the regulation of INO1
expression. The human homolog of yeast KCS1 is h-IP6K (Saiardi et al., 1999).
Two human VIP1-like IP6 kinases have also been cloned and characterized
(Fridy et al., 2007). Both of these IP6 kinases convert IP6 to IP7 (Saiardi et al.,
1999; Fridy et al., 2007). The route by which animals synthesize IP6 is similar to
that used by yeast. In contrast to slime moulds and plants, which synthesize IP6
by stepwise phosphorylation directly from inositol, animals incorporate the first
three phosphates while the inositol is in its lipid form. That is, I(1,4,5)P3 formed
by PLC catalyzed cleavage of PI-(4,5)P2 is sequentially phosphorylated to IP6.
Therefore, human homologs of KCS1 and VIP1 may play similar roles in inositol
metabolism as the counterparts yeast.
The human INO80 (hINO80) chromatin remodeling contains eight
subunits orthologous to yeast, including Ino80 ATPase (Jin et al., 2005), as well
as additional metazoan-specific subunits (Kobor et al., 2004; Kusch 2004). The
cloning, expression, and functional activity of the hINO80 gene revealed its DNA
dependent ATPase and DNA binding activity (Bakshi et al., 2006). There are no
studies regarding the role of the hINO80 complex or IP6 in h-INO1 expression.
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However, if the roles of IP6 and hINO80 in inositol biosynthesis are conserved
from yeast to humans, we can speculate that mutations in human homologs of
KCS1 and VIP1 may affect patients’ responsiveness and resistance to VPA.
An important unanswered question is if decreased INO1 expression in the
kcs1∆ and vip1∆ mutants leads to decreased intracellular inositol. It would also
be interesting to determine if over expression of KCS1 and VIP1 affects
sensitivity to VPA. Finally, an analysis of IP6 levels in all of the mutants of IP
synthesis would help to elucidate the mechanism underlying altered INO1
expression in mutants of IP synthesis.
In summary, my data show that KCS1 and VIP1 are required for optimal
synthesis of inositol, and that loss of these genes leads to sensitivity to VPA. This
finding may have implications for responsiveness to VPA. About half of BD
patients do not respond to VPA for reasons that have not been identified
(Dilsaver at al., 1993). Mutations in genes that affect inositol metabolism, such as
KCS1 and VIP1, may affect patients’ responsiveness to VPA. Understanding the
genetic factors that affect the responsiveness to VPA would contribute greatly to
improving treatment efficacy for BD.
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Bipolar disorder (BD) is a chronic psychiatric illness affecting at least 1%
of the world population. BD is ranked as the sixth greatest cause of death or
disability globally. The cause of BD is unknown. Although the anticonvulsant
valproate (VPA) is widely used as a mood stabilizer to treat BD, VPA is not
completely effective and causes numerous side effects. Hence, it is important to
develop more effective drugs with fewer side effects to treat BD. However, drug
development is hampered by the lack of knowledge of the therapeutic
mechanisms of action of current drugs used to treat BD.
VPA depletes inositol in yeast and mammals. The current study was
undertaken to determine whether genes affecting inositol synthesis lead to VPA
sensitivity.1D-myo-inositol-3 phosphate synthase (MIPS) encoded by INO1
converts glucose-6-phosphate to L-myo-inositol-3-phosphate (MIP) in the de
novo synthesis of inositol. The activation of INO1 expression is positively
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regulated by the INO80 complex, which is inhibited by IP6. KCS1 and VIP1 are
inositol hexakisphosphate kinases that convert IP6 to IP7.
I found that kcs1∆ is an inositol auxotroph and vip1∆ is a partial inositol
auxotroph. Both kcs1∆ and vip1∆ mutants exhibited hypersensitivity to VPA. I
also found that loss of KCS1 and VIP1 cause decreased INO1 expression. The
results of the study suggested that perturbation of IP synthesis exacerbates VPA
induced inositol depletion. These findings have implications for understanding the
mechanisms underlying responsiveness or resistance to VPA in bipolar patients.
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